Ketamine Therapy for PTSD and Depression: Legal Standards and Coverage Considerations in Alabama Workers’ Compensation  

Post-traumatic stress disorder  and depression are frequently at issue in workers’ compensation claims, often giving rise to complex questions regarding the appropriate course of treatment. While traditional modalities such as counseling and daily prescription medications can be effective for some individuals, these treatments do not always provide consistent or lasting relief. As a result, there has been a growing trend within the medical community toward the off-label use of ketamine as an alternative treatment option for PTSD and depression, with early studies and clinic reports indicating potentially promising outcomes. However, within the framework of Alabama workers’ compensation law, a critical issue remains: whether the off-label use of ketamine constitutes reasonable and necessary medical treatment such that it should be compensable under the Alabama Workers’ Compensation Act.  

To address these questions, it is first necessary to understand ketamine and its historical and clinical background. Ketamine is a potent dissociative anesthetic and a type of hallucinogen known to distort visual and auditory perception while producing feelings of detachment from both the surrounding environment and one’s sense of self. Since the 1970s, physicians in the United States have utilized ketamine as a short-acting injectable anesthetic, including for pain management and procedural sedation. However, the same properties that make ketamine an effective anesthetic and sedative also contribute to its potential for misuse and illicit distribution, where it is commonly referred to by street names such as “Special K,” “K,” and “Vitamin K.” In fact, ketamine was classified as a Schedule III nonnarcotic controlled substance under the Controlled Substances Act in 1999. Moreover, long-term use or abuse of ketamine has been associated with memory impairment, depression and severe bladder damage while concurrent use with alcohol, opioids or benzodiazepines can significantly increase the risk of respiratory depression, which may be fatal. 

More recently, in 2019, esketamine, a derivative of ketamine marketed as Spravato, received approval from the U.S. Food and Drug Administration for use in patients with treatment-resistant depression, provided that it is administered in certified clinical settings under appropriate supervision. Notwithstanding this development, while physicians continue to utilize ketamine in traditional clinical contexts such as short-term sedation and anesthesia, no form of ketamine has been approved by the FDA for the treatment of PTSD. Nevertheless, despite the absence of such approval, there has been a growing trend within the medical community toward the “off-label” use of ketamine in the treatment of PTSD and depression. 

Given this off-label usage, the question of an employer’s responsibility to cover ketamine prescribed by an authorized treating physician for a work-related mental health condition in Alabama becomes particularly complex from a workers’ compensation perspective. Under Alabama law, an employer is generally required to provide medical treatment that is reasonably necessary and recommended by the ATP. At the same time, the Alabama Workers’ Compensation Act permits an employer to challenge or decline payment for treatment that is not “reasonably necessary.” The statute further contemplates that medical necessity may include services with “scientifically established medical value,” thereby reflecting a broader inquiry than FDA approval alone. Importantly, the act does not make FDA approval a prerequisite to compensability. Accordingly, where a treatment such as ketamine is supported by scientifically recognized medical evidence or has become integrated into accepted clinical practice, the absence of FDA approval by itself is not determinative and does not automatically relieve an employer of responsibility for coverage under the act. 

This standard becomes particularly difficult to apply in the context of ketamine as the exiting medical literature regarding its use for PTSD and depression remains mixed and continues to evolve. While some studies and clinical reports suggest potential therapeutic benefit, others emphasize the limitations of the current evidence base and the need for further research to establish long-term efficacy and safety. Compounding this uncertainty, the Alabama State Board of Medical Examiners had issued guidance acknowledging that although ketamine is not currently FDA-approved for the treatment of any mental health condition, including PTSD, related treatments such as esketamine may be appropriately administered in specific medical settings by qualified practitioners under controlled conditions.  

Because the act requires employers to provide medical treatment that is reasonably necessary while also permitting them to contest or decline treatment that does not meet that standard, the appropriate mechanism for resolving such disputes becomes critical. Alabama law provides a structured process for challenging recommended treatment through utilization review, which allows an employer to obtain an independent assessment of whether the proposed treatment is medically appropriate under the circumstances. If utilization review concludes that the treatment is not recommended or not medically necessary, the employer may rely on that determination in denying the requested treatment as not reasonably necessary under the act. However, these determinations are not binding or final as the employee may still seek review by the court, which retains the ultimate authority to determine medical necessity and, where appropriate, compel the provision of treatment.  

Despite these risks, ketamine and ketamine-derived therapies are increasingly emerging as potential treatment options within the workers’ compensation context. Coverage determinations are highly fact-specific and require careful evaluation of the medical evidence, including the opinions and recommendations of the authorized treating physicians, as well as applicable statutory and case law standards. While no bright-line rule governs the approval of such treatment requests, these considerations collectively form the analytical framework for assessing whether such treatment is reasonable and necessary under the circumstances of each individual claim. 

Delaney Holmes is an associate attorney at Swift Currie in Birmingham, Alabama. She represents employers, insurers and self-insureds in workers’ compensation and general liability maters. Delaney can be reached at delaney.holmes@swiftcurriecom. 

Share This Article: